Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Ann Surg. 2022 Aug 1;276(2):298-304. doi: 10.1097/SLA.0000000000004436. Epub 2020 Oct 16.
This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC.
To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease.
Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses.
Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.25 ( P < 0.001)/0.17 ( P < 0.001)/0.16 ( P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.26 ( P < 0.001)/0.12 ( P < 0.001)/0.11 ( P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade 1b (60%)/2 (67%)/3 (67%) whereas less than 25% in Grade 0 or 1a.
It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.
本研究旨在阐明对新辅助化疗(NAC)有反应的食管鳞癌(ESCC)患者的残留疾病分布和复发模式。
为了适当规划针对包括对 NAC 有反应的患者在内的器官保存方法的前瞻性试验,需要阐明残留疾病的分布情况。鉴于残留肿瘤位于区域内,可安全地添加放化疗以消除残留疾病。
共对 2 家高容量中心的 483 例接受 NAC 治疗后行经胸食管切除术的可切除 ESCC 患者进行了回顾性分析。比较了病理反应患者之间的无复发生存率、总生存率(OS)以及残留和复发性肿瘤模式。
与非病理反应者相比,病理反应者的无复发生存率[1b/2/3 级与 0 级相比的危险比(HR);0.25(P<0.001)/0.17(P<0.001)/0.16(P=0.003)]和 OS[1b/2/3 级与 0 级相比的 HR;0.26(P<0.001)/0.12(P<0.001)/0.11(P=0.003)]显著延长。就复发的分布而言,1b 级(60%)/2 级(67%)/3 级(67%)患者中,区域复发中孤立复发的比例明显高于 0 级或 1a 级(<25%)。
研究发现,有反应者的术后复发主要发生在区域内,多为孤立性病变,无远处失败,提示残留肿瘤细胞可通过额外的放化疗消除。